한글목차

세계의 헤파린 시장 규모는 2024년에 12억 2,500만 달러로 추정되며, 2025-2031년의 예측 기간에 CAGR 7.8%로 확대하며, 2031년까지 23억 100만 달러로 재조정될 전망입니다.

이 보고서는 헤파린의 국경 간 산업적 발자취, 자본 배분 패턴, 지역 경제의 상호 의존성, 공급망 재구축에 대한 최근 관세 조정 및 국제적인 전략적 대응 조치에 대한 종합적인 평가를 제공합니다.

2024년 세계 헤파린 생산량은 약 23조 4,980억 단위, 세계 평균 시장 가격은 10억 단위당 약 5만 2,147달러에 달했습니다. 헤파린은 항응고제(혈액을 묽게 하는 약제)로 혈전 형성을 방지합니다. 정맥, 동맥 또는 폐의 혈전 치료 및 예방에 사용됩니다. 또한 수술 전 혈전 위험 감소에도 사용됩니다. 헤파린 제품의 대부분은 헤파린 나트륨 또는 헤파린 칼슘의 형태로 존재합니다. 이 보고서에서는 주로 헤파린 원료의약품(API)에 대해 조사했습니다.

헤파린의 세계 주요 기업으로는 Shenzhen Hepalink Pharmaceutical, Yantai Dongcheng Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Pfizer, Hebei Changshan Biochemical Pharmaceutical 등을 들 수 있습니다. Hebei Changshan Biochemical Pharmaceutical 등이 있습니다. 상위 5개사의 점유율은 약 54%를 차지하고 있습니다. 중국은 세계 헤파린 시장을 독점하고 있으며, 생산량 기준으로 65% 이상의 점유율을 차지하고 있습니다. 유럽과 아시아태평양이 양대 시장으로 약 34%의 점유율을 차지하고 있으며, 그 다음으로 북미가 약 30%의 점유율을 차지하고 있습니다.

헤파린 원료의약품 시장의 주요 성장 요인은 전 세계에서 심혈관 질환 및 혈전색전증 유병률 증가와 수술 건수 증가입니다. 고령화와 비만율 증가는 항응고제의 지속적인 수요를 지원하고 있습니다. 또한 COVID-19 관련 혈전성 합병증 치료에 헤파린의 사용이 시장 확대를 더욱 촉진하고 있습니다. 중국, 인도 등 신흥 시장에서의 제약산업 발전과 바이오의약품 분야에서의 고품질 헤파린 수요도 시장 성장을 촉진하고 있습니다.

헤파린 원료의약품 시장의 주요 동향은 다음과 같습니다: 1, 동물성 헤파린(돼지 장 점막 추출)에서 합성 대체품(예: 저분자량 헤파린)으로의 기술적 전환. 2, 공급망 추적성 및 품질관리에 대한 엄격한 규제 요건. 3, 바이오시밀러로 인한 경쟁 심화로 인한 공정 최적화 및 비용 절감 추진. 4, 신흥 시장 현지 제약사의 부상으로 인한 세계 헤파린 공급망 다변화.

이 보고서는 헤파린 세계 시장에 대한 종합적인 분석을 제공하는 것을 목표로 합니다. 총판매량, 매출, 가격, 주요 기업의 시장 점유율 및 순위에 초점을 맞추고, 지역 및 국가별, 유형별, 용도별 헤파린 분석을 포함합니다.

이 보고서는 헤파린 시장 규모, 추정치, 예측치를 판매량(10억 단위) 및 매출액(백만 달러)으로 제시하고, 2024년을 기준 연도로 하여 2020-2031년의 과거 데이터와 예측 데이터를 포함하고 있습니다. 정량적, 정성적 분석을 통해 독자들이 헤파린 관련 사업 전략 및 성장 전략 수립, 시장 경쟁 평가, 현재 시장에서의 자사 포지셔닝 분석, 정보에 입각한 사업적 판단을 내릴 수 있도록 도와드립니다.

시장 세분화

기업별

• Shenzhen Hepalink Pharmaceutical
• Yantai Dongcheng Pharmaceutical
• Pfizer
• Bioiberica
• Changzhou Qianhong Biopharma
• Nanjing King-friend Biochemical Pharmaceutical
• Hebei Changshan Biochemical Pharmaceutical
• Qingdao Jiulong Biopharmaceutical
• Opocrin
• Dongying Tiandong Pharmaceutical
• Aspen Oss
• Yino Pharma
• Nanjing Xinbai Pharmaceutical
• Hubei Enoray Biopharmaceutical
• Cisen Pharmaceutical

유형별 부문

• 헤파린 나트륨
• 헤파린 칼슘

용도별 부문

• UFH
• 저분자 헤파린

지역별

• 북미
  • 미국
  • 캐나다
• 아시아태평양
  • 중국
  • 일본
  • 한국
  • 동남아시아
  • 인도
  • 호주
  • 기타 아시아태평양
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 네덜란드
  • 북유럽 국가
  • 기타 유럽
• 라틴아메리카
  • 멕시코
  • 브라질
  • 기타 라틴아메리카
• 중동 및 아프리카
  • 튀르키예
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동 및 아프리카

영문목차

The global market for Heparin was estimated to be worth US$ 1225 million in 2024 and is forecast to a readjusted size of US$ 2301 million by 2031 with a CAGR of 7.8% during the forecast period 2025-2031.

This report provides a comprehensive assessment of recent tariff adjustments and international strategic countermeasures on Heparin cross-border industrial footprints, capital allocation patterns, regional economic interdependencies, and supply chain reconfigurations.

In 2024, global Heparin production reached approximately 23,498 billion units , with an average global market price of around US$ 52,147 per billion units. Heparin is an anticoagulant (blood thinner) that prevents the formation of blood clots. Heparin is used to treat and prevent blood clots in the veins, arteries, or lung. It is also used before surgery to reduce the risk of blood clots. Most of the Heparin product is existed in a form of Heparin Sodium or Heparin Calcium. In this report, we mainly study the Heparin API.

Global key players of Heparin include Shenzhen Hepalink Pharmaceutical, Yantai Dongcheng Pharmaceutical, Nanjing King-friend Biochemical Pharmaceutical, Pfizer, Hebei Changshan Biochemical Pharmaceutical, etc. The top five manufacturers hold a share about 54%. China is dominating the global Heparin market, has a share over 65% in terms of production. Europe and Asia-Pacific are the two largest market, both having a share about 34%, followed by North America, with a share about 30 percent.

The heparin API market is primarily driven by the rising global prevalence of cardiovascular and thromboembolic diseases, along with increasing surgical procedures. Growing aging populations and higher obesity rates contribute to sustained demand for anticoagulants. Additionally, heparin's use in treating COVID-19-associated thrombotic complications has further propelled market expansion. Pharmaceutical industry advancements in emerging markets (e.g., China and India) and the biopharmaceutical sector's demand for high-quality heparin also fuel market growth.

Key trends in the heparin API market include: 1) a technological shift from animal-sourced heparin (porcine intestinal mucosa extraction) to synthetic alternatives (e.g., low-molecular-weight heparin); 2) stringent regulatory requirements for supply chain traceability and quality control; 3) intensified competition from biosimilars, driving process optimization and cost reduction; and 4) the rise of local pharmaceutical players in emerging markets, diversifying the global heparin supply chain.

This report aims to provide a comprehensive presentation of the global market for Heparin, focusing on the total sales volume, sales revenue, price, key companies market share and ranking, together with an analysis of Heparin by region & country, by Type, and by Application.

The Heparin market size, estimations, and forecasts are provided in terms of sales volume (billion units) and sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Heparin.

Market Segmentation

By Company

• Shenzhen Hepalink Pharmaceutical
• Yantai Dongcheng Pharmaceutical
• Pfizer
• Bioiberica
• Changzhou Qianhong Biopharma
• Nanjing King-friend Biochemical Pharmaceutical
• Hebei Changshan Biochemical Pharmaceutical
• Qingdao Jiulong Biopharmaceutical
• Opocrin
• Dongying Tiandong Pharmaceutical
• Aspen Oss
• Yino Pharma
• Nanjing Xinbai Pharmaceutical
• Hubei Enoray Biopharmaceutical
• Cisen Pharmaceutical

Segment by Type

• Heparin Sodium
• Heparin Calcium

Segment by Application

• UFH
• LMWH

By Region

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • South Korea
  • Southeast Asia
  • India
  • Australia
  • Rest of Asia-Pacific
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Netherlands
  • Nordic Countries
  • Rest of Europe
• Latin America
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa
  • Turkey
  • Saudi Arabia
  • UAE
  • Rest of MEA

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size (value, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 2: Detailed analysis of Heparin manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5: Sales, revenue of Heparin in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 6: Sales, revenue of Heparin in country level. It provides sigmate data by Type, and by Application for each country/region.

Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 9: Conclusion.

Table of Contents

1 Market Overview

• 1.1 Heparin Product Introduction
• 1.2 Global Heparin Market Size Forecast
  • 1.2.1 Global Heparin Sales Value (2020-2031)
  • 1.2.2 Global Heparin Sales Volume (2020-2031)
  • 1.2.3 Global Heparin Sales Price (2020-2031)
• 1.3 Heparin Market Trends & Drivers
  • 1.3.1 Heparin Industry Trends
  • 1.3.2 Heparin Market Drivers & Opportunity
  • 1.3.3 Heparin Market Challenges
  • 1.3.4 Heparin Market Restraints
• 1.4 Assumptions and Limitations
• 1.5 Study Objectives
• 1.6 Years Considered

2 Competitive Analysis by Company

• 2.1 Global Heparin Players Revenue Ranking (2024)
• 2.2 Global Heparin Revenue by Company (2020-2025)
• 2.3 Global Heparin Players Sales Volume Ranking (2024)
• 2.4 Global Heparin Sales Volume by Company Players (2020-2025)
• 2.5 Global Heparin Average Price by Company (2020-2025)
• 2.6 Key Manufacturers Heparin Manufacturing Base and Headquarters
• 2.7 Key Manufacturers Heparin Product Offered
• 2.8 Key Manufacturers Time to Begin Mass Production of Heparin
• 2.9 Heparin Market Competitive Analysis
  • 2.9.1 Heparin Market Concentration Rate (2020-2025)
  • 2.9.2 Global 5 and 10 Largest Manufacturers by Heparin Revenue in 2024
  • 2.9.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Heparin as of 2024)
• 2.10 Mergers & Acquisitions, Expansion

3 Segmentation by Type

• 3.1 Introduction by Type
  • 3.1.1 Heparin Sodium
  • 3.1.2 Heparin Calcium
• 3.2 Global Heparin Sales Value by Type
  • 3.2.1 Global Heparin Sales Value by Type (2020 VS 2024 VS 2031)
  • 3.2.2 Global Heparin Sales Value, by Type (2020-2031)
  • 3.2.3 Global Heparin Sales Value, by Type (%) (2020-2031)
• 3.3 Global Heparin Sales Volume by Type
  • 3.3.1 Global Heparin Sales Volume by Type (2020 VS 2024 VS 2031)
  • 3.3.2 Global Heparin Sales Volume, by Type (2020-2031)
  • 3.3.3 Global Heparin Sales Volume, by Type (%) (2020-2031)
• 3.4 Global Heparin Average Price by Type (2020-2031)

4 Segmentation by Application

• 4.1 Introduction by Application
  • 4.1.1 UFH
  • 4.1.2 LMWH
• 4.2 Global Heparin Sales Value by Application
  • 4.2.1 Global Heparin Sales Value by Application (2020 VS 2024 VS 2031)
  • 4.2.2 Global Heparin Sales Value, by Application (2020-2031)
  • 4.2.3 Global Heparin Sales Value, by Application (%) (2020-2031)
• 4.3 Global Heparin Sales Volume by Application
  • 4.3.1 Global Heparin Sales Volume by Application (2020 VS 2024 VS 2031)
  • 4.3.2 Global Heparin Sales Volume, by Application (2020-2031)
  • 4.3.3 Global Heparin Sales Volume, by Application (%) (2020-2031)
• 4.4 Global Heparin Average Price by Application (2020-2031)

5 Segmentation by Region

• 5.1 Global Heparin Sales Value by Region
  • 5.1.1 Global Heparin Sales Value by Region: 2020 VS 2024 VS 2031
  • 5.1.2 Global Heparin Sales Value by Region (2020-2025)
  • 5.1.3 Global Heparin Sales Value by Region (2026-2031)
  • 5.1.4 Global Heparin Sales Value by Region (%), (2020-2031)
• 5.2 Global Heparin Sales Volume by Region
  • 5.2.1 Global Heparin Sales Volume by Region: 2020 VS 2024 VS 2031
  • 5.2.2 Global Heparin Sales Volume by Region (2020-2025)
  • 5.2.3 Global Heparin Sales Volume by Region (2026-2031)
  • 5.2.4 Global Heparin Sales Volume by Region (%), (2020-2031)
• 5.3 Global Heparin Average Price by Region (2020-2031)
• 5.4 North America
  • 5.4.1 North America Heparin Sales Value, 2020-2031
  • 5.4.2 North America Heparin Sales Value by Country (%), 2024 VS 2031
• 5.5 Europe
  • 5.5.1 Europe Heparin Sales Value, 2020-2031
  • 5.5.2 Europe Heparin Sales Value by Country (%), 2024 VS 2031
• 5.6 Asia Pacific
  • 5.6.1 Asia Pacific Heparin Sales Value, 2020-2031
  • 5.6.2 Asia Pacific Heparin Sales Value by Region (%), 2024 VS 2031
• 5.7 South America
  • 5.7.1 South America Heparin Sales Value, 2020-2031
  • 5.7.2 South America Heparin Sales Value by Country (%), 2024 VS 2031
• 5.8 Middle East & Africa
  • 5.8.1 Middle East & Africa Heparin Sales Value, 2020-2031
  • 5.8.2 Middle East & Africa Heparin Sales Value by Country (%), 2024 VS 2031

6 Segmentation by Key Countries/Regions

• 6.1 Key Countries/Regions Heparin Sales Value Growth Trends, 2020 VS 2024 VS 2031
• 6.2 Key Countries/Regions Heparin Sales Value and Sales Volume
  • 6.2.1 Key Countries/Regions Heparin Sales Value, 2020-2031
  • 6.2.2 Key Countries/Regions Heparin Sales Volume, 2020-2031
• 6.3 United States
  • 6.3.1 United States Heparin Sales Value, 2020-2031
  • 6.3.2 United States Heparin Sales Value by Type (%), 2024 VS 2031
  • 6.3.3 United States Heparin Sales Value by Application, 2024 VS 2031
• 6.4 Europe
  • 6.4.1 Europe Heparin Sales Value, 2020-2031
  • 6.4.2 Europe Heparin Sales Value by Type (%), 2024 VS 2031
  • 6.4.3 Europe Heparin Sales Value by Application, 2024 VS 2031
• 6.5 China
  • 6.5.1 China Heparin Sales Value, 2020-2031
  • 6.5.2 China Heparin Sales Value by Type (%), 2024 VS 2031
  • 6.5.3 China Heparin Sales Value by Application, 2024 VS 2031
• 6.6 Japan
  • 6.6.1 Japan Heparin Sales Value, 2020-2031
  • 6.6.2 Japan Heparin Sales Value by Type (%), 2024 VS 2031
  • 6.6.3 Japan Heparin Sales Value by Application, 2024 VS 2031
• 6.7 South Korea
  • 6.7.1 South Korea Heparin Sales Value, 2020-2031
  • 6.7.2 South Korea Heparin Sales Value by Type (%), 2024 VS 2031
  • 6.7.3 South Korea Heparin Sales Value by Application, 2024 VS 2031
• 6.8 Southeast Asia
  • 6.8.1 Southeast Asia Heparin Sales Value, 2020-2031
  • 6.8.2 Southeast Asia Heparin Sales Value by Type (%), 2024 VS 2031
  • 6.8.3 Southeast Asia Heparin Sales Value by Application, 2024 VS 2031
• 6.9 India
  • 6.9.1 India Heparin Sales Value, 2020-2031
  • 6.9.2 India Heparin Sales Value by Type (%), 2024 VS 2031
  • 6.9.3 India Heparin Sales Value by Application, 2024 VS 2031

7 Company Profiles

• 7.1 Shenzhen Hepalink Pharmaceutical
  • 7.1.1 Shenzhen Hepalink Pharmaceutical Company Information
  • 7.1.2 Shenzhen Hepalink Pharmaceutical Introduction and Business Overview
  • 7.1.3 Shenzhen Hepalink Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.1.4 Shenzhen Hepalink Pharmaceutical Heparin Product Offerings
  • 7.1.5 Shenzhen Hepalink Pharmaceutical Recent Development
• 7.2 Yantai Dongcheng Pharmaceutical
  • 7.2.1 Yantai Dongcheng Pharmaceutical Company Information
  • 7.2.2 Yantai Dongcheng Pharmaceutical Introduction and Business Overview
  • 7.2.3 Yantai Dongcheng Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.2.4 Yantai Dongcheng Pharmaceutical Heparin Product Offerings
  • 7.2.5 Yantai Dongcheng Pharmaceutical Recent Development
• 7.3 Pfizer
  • 7.3.1 Pfizer Company Information
  • 7.3.2 Pfizer Introduction and Business Overview
  • 7.3.3 Pfizer Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.3.4 Pfizer Heparin Product Offerings
  • 7.3.5 Pfizer Recent Development
• 7.4 Bioiberica
  • 7.4.1 Bioiberica Company Information
  • 7.4.2 Bioiberica Introduction and Business Overview
  • 7.4.3 Bioiberica Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.4.4 Bioiberica Heparin Product Offerings
  • 7.4.5 Bioiberica Recent Development
• 7.5 Changzhou Qianhong Biopharma
  • 7.5.1 Changzhou Qianhong Biopharma Company Information
  • 7.5.2 Changzhou Qianhong Biopharma Introduction and Business Overview
  • 7.5.3 Changzhou Qianhong Biopharma Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.5.4 Changzhou Qianhong Biopharma Heparin Product Offerings
  • 7.5.5 Changzhou Qianhong Biopharma Recent Development
• 7.6 Nanjing King-friend Biochemical Pharmaceutical
  • 7.6.1 Nanjing King-friend Biochemical Pharmaceutical Company Information
  • 7.6.2 Nanjing King-friend Biochemical Pharmaceutical Introduction and Business Overview
  • 7.6.3 Nanjing King-friend Biochemical Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.6.4 Nanjing King-friend Biochemical Pharmaceutical Heparin Product Offerings
  • 7.6.5 Nanjing King-friend Biochemical Pharmaceutical Recent Development
• 7.7 Hebei Changshan Biochemical Pharmaceutical
  • 7.7.1 Hebei Changshan Biochemical Pharmaceutical Company Information
  • 7.7.2 Hebei Changshan Biochemical Pharmaceutical Introduction and Business Overview
  • 7.7.3 Hebei Changshan Biochemical Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.7.4 Hebei Changshan Biochemical Pharmaceutical Heparin Product Offerings
  • 7.7.5 Hebei Changshan Biochemical Pharmaceutical Recent Development
• 7.8 Qingdao Jiulong Biopharmaceutical
  • 7.8.1 Qingdao Jiulong Biopharmaceutical Company Information
  • 7.8.2 Qingdao Jiulong Biopharmaceutical Introduction and Business Overview
  • 7.8.3 Qingdao Jiulong Biopharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.8.4 Qingdao Jiulong Biopharmaceutical Heparin Product Offerings
  • 7.8.5 Qingdao Jiulong Biopharmaceutical Recent Development
• 7.9 Opocrin
  • 7.9.1 Opocrin Company Information
  • 7.9.2 Opocrin Introduction and Business Overview
  • 7.9.3 Opocrin Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.9.4 Opocrin Heparin Product Offerings
  • 7.9.5 Opocrin Recent Development
• 7.10 Dongying Tiandong Pharmaceutical
  • 7.10.1 Dongying Tiandong Pharmaceutical Company Information
  • 7.10.2 Dongying Tiandong Pharmaceutical Introduction and Business Overview
  • 7.10.3 Dongying Tiandong Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.10.4 Dongying Tiandong Pharmaceutical Heparin Product Offerings
  • 7.10.5 Dongying Tiandong Pharmaceutical Recent Development
• 7.11 Aspen Oss
  • 7.11.1 Aspen Oss Company Information
  • 7.11.2 Aspen Oss Introduction and Business Overview
  • 7.11.3 Aspen Oss Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.11.4 Aspen Oss Heparin Product Offerings
  • 7.11.5 Aspen Oss Recent Development
• 7.12 Yino Pharma
  • 7.12.1 Yino Pharma Company Information
  • 7.12.2 Yino Pharma Introduction and Business Overview
  • 7.12.3 Yino Pharma Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.12.4 Yino Pharma Heparin Product Offerings
  • 7.12.5 Yino Pharma Recent Development
• 7.13 Nanjing Xinbai Pharmaceutical
  • 7.13.1 Nanjing Xinbai Pharmaceutical Company Information
  • 7.13.2 Nanjing Xinbai Pharmaceutical Introduction and Business Overview
  • 7.13.3 Nanjing Xinbai Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.13.4 Nanjing Xinbai Pharmaceutical Heparin Product Offerings
  • 7.13.5 Nanjing Xinbai Pharmaceutical Recent Development
• 7.14 Hubei Enoray Biopharmaceutical
  • 7.14.1 Hubei Enoray Biopharmaceutical Company Information
  • 7.14.2 Hubei Enoray Biopharmaceutical Introduction and Business Overview
  • 7.14.3 Hubei Enoray Biopharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.14.4 Hubei Enoray Biopharmaceutical Heparin Product Offerings
  • 7.14.5 Hubei Enoray Biopharmaceutical Recent Development
• 7.15 Cisen Pharmaceutical
  • 7.15.1 Cisen Pharmaceutical Company Information
  • 7.15.2 Cisen Pharmaceutical Introduction and Business Overview
  • 7.15.3 Cisen Pharmaceutical Heparin Sales, Revenue, Price and Gross Margin (2020-2025)
  • 7.15.4 Cisen Pharmaceutical Heparin Product Offerings
  • 7.15.5 Cisen Pharmaceutical Recent Development

8 Industry Chain Analysis

• 8.1 Heparin Industrial Chain
• 8.2 Heparin Upstream Analysis
  • 8.2.1 Key Raw Materials
  • 8.2.2 Raw Materials Key Suppliers
  • 8.2.3 Manufacturing Cost Structure
• 8.3 Midstream Analysis
• 8.4 Downstream Analysis (Customers Analysis)
• 8.5 Sales Model and Sales Channels
  • 8.5.1 Heparin Sales Model
  • 8.5.2 Sales Channel
  • 8.5.3 Heparin Distributors

9 Research Findings and Conclusion

10 Appendix

• 10.1 Research Methodology
  • 10.1.1 Methodology/Research Approach
    • 10.1.1.1 Research Programs/Design
    • 10.1.1.2 Market Size Estimation
    • 10.1.1.3 Market Breakdown and Data Triangulation
  • 10.1.2 Data Source
    • 10.1.2.1 Secondary Sources
    • 10.1.2.2 Primary Sources
• 10.2 Author Details
• 10.3 Disclaimer